Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Paolo Antonio Ascierto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

Cortellini, A., Bersanelli, M., Santini, D., Buti, S., Tiseo, M., Cannita, K., Perrone, F., Giusti, R., De Tursi, M., Zoratto, F., Marconcini, R., Russano, M., Zeppola, T., Anesi, C., Filetti, M., Marchetti, P., Botticelli, A., Gelibter, A., De Galitiis, F., Vitale, M. G. & 18 others, Rastelli, F., Tudini, M., Silva, R. R., Atzori, F., Chiari, R., Ricciuti, B., De Giglio, A., Migliorino, M. R., Mallardo, D., Vanella, V., Mosillo, C., Bracarda, S., Rinaldi, S., Berardi, R., Natoli, C., Ficorella, C., Porzio, G. & Ascierto, P. A., Feb 4 2020, In : Eur. J. Cancer. 128, p. 17-26 10 p.

Research output: Contribution to journalArticle

  • Anti-IL6R role in treatment of COVID-19-related ARDS

    Buonaguro, F. M., Puzanov, I. & Ascierto, P. A., Apr 14 2020, In : Journal of Translational Medicine. 18, 1, 165.

    Research output: Contribution to journalEditorial

    Open Access

    Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

    Eggermont, A. M. M., Kicinski, M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., Van Den Eertwegh, A. J. M. & 10 others, Grob, J. J., Gutzmer, R., Jamal, R., Lorigan, P. C., Krepler, C., Ibrahim, N., Marreaud, S., Van Akkooi, A., Robert, C. & Suciu, S., Apr 2020, In : JAMA oncology. 6, 4, p. 519-527 9 p.

    Research output: Contribution to journalArticle

    Open Access
  • Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

    Gutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L., Manikhas, G. M., Yan, Y., Huang, K. C., Uyei, A., McNally, V., McArthur, G. A. & Ascierto, P. A., Jun 13 2020, In : The Lancet. 395, 10240, p. 1835-1844 10 p.

    Research output: Contribution to journalArticle

  • Biology confirmed but biomarkers elusive in melanoma immunotherapy

    Luke, J. J. & Ascierto, P. A., 2020, In : Nature Reviews Clinical Oncology.

    Research output: Contribution to journalComment/debate